"This will now have a considerable deterrent value both in the UK and elsewhere. In addition, there would be cost benefits to Comvita in any subsequent revocation proceedings which might be launched against the patent in the UK or elsewhere," he said.
Apimed and Brightwake Limited (trading as Advancis Medical) settled Apimed's claim for patent infringement in respect of Brightwake's Algivon product last September. This grants Brightwake a sub-licence to manufacture, distribute and sell its Algivon products in the UK, Europe, New Zealand, Australia, South Africa, Singapore and Japan. This sub-licence does not include the United States or Canada.